HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Monica Arnedos Selected Research

Therapeutics

4/2024Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.
1/2024p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane.
3/2023Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort.
1/2022High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
1/2021Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.
1/2021Optimizing the Management of Cancer Patients Treated With Systemic Therapies During the COVID-19 Pandemic: The New Role of PCR and CT Scan.
11/2019Window of Opportunity trials for biomarker discovery in breast cancer.
10/2017Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients.
6/2015Targeted therapies for ER+/HER2- metastatic breast cancer.
2/2014Clinical development of mTOR inhibitors in breast cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Monica Arnedos Research Topics

Disease

31Breast Neoplasms (Breast Cancer)
04/2024 - 04/2007
21Neoplasms (Cancer)
01/2023 - 12/2007
3Triple Negative Breast Neoplasms
01/2023 - 07/2012
2Disease Progression
04/2024 - 01/2020
2Neoplasm Metastasis (Metastasis)
03/2023 - 02/2011
2Lobular Carcinoma
07/2014 - 02/2011
1Brain Neoplasms (Brain Tumor)
04/2024
1Exanthema (Rash)
10/2021
1Mucositis
10/2021
1COVID-19
01/2021
1Aneuploidy (Aneuploid)
11/2019
1Rare Diseases (Rare Disease)
01/2014
1Carcinoma (Carcinomatosis)
02/2011
1Pain (Aches)
11/2008
1Sepsis (Septicemia)
11/2008
1Neutropenia
11/2008
1Infertility (Sterility)
08/2008

Drug/Important Bio-Agent (IBA)

10Biomarkers (Surrogate Marker)IBA
01/2024 - 02/2011
6Trastuzumab (Herceptin)FDA Link
04/2024 - 02/2014
6Hormones (Hormone)IBA
01/2024 - 11/2007
5Estrogen ReceptorsIBA
01/2022 - 07/2012
4DNA (Deoxyribonucleic Acid)IBA
10/2022 - 06/2012
4ErbB Receptors (EGF Receptor)IBA
01/2021 - 03/2012
3EverolimusFDA Link
01/2024 - 10/2017
3TOR Serine-Threonine KinasesIBA
01/2024 - 10/2017
3Letrozole (Femara)FDA LinkGeneric
11/2014 - 11/2007
2exemestane (Aromasin)FDA Link
01/2024 - 11/2007
2Taxoids (Taxanes)IBA
01/2023 - 11/2019
2GenieIBA
01/2022 - 01/2020
2Poly(ADP-ribose) Polymerase InhibitorsIBA
12/2021 - 07/2012
2Antineoplastic Agents (Antineoplastics)IBA
01/2021 - 11/2013
2Fulvestrant (Faslodex)FDA Link
01/2020 - 10/2019
2Phosphotransferases (Kinase)IBA
01/2020 - 03/2012
2Paclitaxel (Taxol)FDA LinkGeneric
11/2019 - 11/2008
2Phenobarbital (Luminal)FDA Link
10/2019 - 05/2015
2Epidermal Growth Factor (EGF)IBA
05/2016 - 02/2014
2Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
03/2013 - 07/2012
2Aromatase InhibitorsIBA
06/2012 - 11/2007
1trastuzumab deruxtecanIBA
04/2024
1tucatinibIBA
04/2024
1Capecitabine (Xeloda)FDA Link
04/2024
1Androgen Antagonists (Antiandrogens)IBA
12/2023
1Androgen Receptors (Androgen Receptor)IBA
12/2023
1pertuzumabIBA
03/2023
1AlpelisibIBA
01/2022
1ribociclibIBA
01/2022
1rucaparibIBA
12/2021
1durvalumabIBA
01/2021
1KetonesIBA
01/2021
1AntibodiesIBA
01/2021
13-Hydroxybutyric Acid (beta-Hydroxybutyric Acid)IBA
01/2021
1B7-H1 AntigenIBA
01/2021
1neratinibIBA
01/2020
1Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
11/2019
1palbociclibIBA
10/2019
1CyclinsIBA
10/2019
1Mechanistic Target of Rapamycin Complex 1IBA
10/2017
1MTOR InhibitorsIBA
02/2014
1Proteins (Proteins, Gene)FDA Link
01/2014
1LigandsIBA
03/2013
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
07/2012
1human ERBB2 proteinIBA
07/2012
1Progesterone Receptors (Progesterone Receptor)IBA
07/2012
1Formaldehyde (Formol)FDA Link
06/2012
1ParaffinIBA
06/2012
1Aromatase (CYP19)IBA
06/2012
1Cyclin-Dependent Kinase 2IBA
03/2012
1Monoclonal AntibodiesIBA
02/2011
1CateninsIBA
02/2011
1Cadherins (E-Cadherin)IBA
02/2011
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
11/2008
1Goserelin (Zoladex)FDA Link
08/2008
1TamoxifenFDA LinkGeneric
12/2007
1Anastrozole (Arimidex)FDA LinkGeneric
11/2007

Therapy/Procedure

15Therapeutics
04/2024 - 04/2007
5Neoadjuvant Therapy
11/2019 - 11/2008
4Adjuvant Chemotherapy
05/2015 - 08/2008
3Drug Therapy (Chemotherapy)
01/2021 - 07/2012
2Precision Medicine
12/2015 - 01/2014
1Ketogenic Diet
01/2021
1Maintenance Chemotherapy
01/2021
1Time-to-Treatment
11/2019
1Conservative Treatment
07/2014
1Mastectomy (Mammectomy)
07/2014
1Aftercare (After-Treatment)
08/2013
1Treatment Delay
11/2008
1Drug Tapering
11/2008